



PELIKAN TECHNOLOGIES APPOINTS DENNY WARE TO BOARD OF DIRECTORS

Newest Board Member Brings Key Operational Experience and Broad Blood Glucose Monitoring Industry Expertise

Palo Alto, CA, May 29, 2008 - Pelikan Technologies Inc., a leading developer of innovative hand-held diagnostic and monitoring devices, today announced the appointment of Dennert (Denny) Ware to its board of directors. Having most recently served as president and chief executive officer of Kinetic Concepts, Inc. (KCI), a global medical technology company, Mr. Ware brings vast operational and relevant industry experience to Pelikan's board. Under his leadership, revenue at KCI grew organically from approximately \$300 million to \$1.4 billion, making it one of the medical technology industry's fastest growing companies.

"We are very excited to have Denny join Pelikan's board," stated Pelikan's president and chief executive officer, Dirk Boecker, M.D., Ph.D. "Not only does he have valuable first-hand experience in the blood glucose monitoring industry, he also has been responsible for generating tremendous revenue growth in the medical technology arena. This expertise will be particularly important for Pelikan as we ramp up our commercialization efforts for the Pelikan Sun™ electronic lancing device, as well as continue our development work on our next-generation, fully-integrated blood glucose system."

Prior to his work at KCI, Mr. Ware served as president and chief executive officer at Boehringer Mannheim Corporation, a market leader in the development and commercialization of innovative medical diagnostic equipment, particularly in the field of glucose monitoring and management for diabetics. Following Boehringer Mannheim's acquisition by F. Hoffman la Roche, he served as chief executive officer of Roche Diagnostics Corporation until joining KCI. Mr. Ware currently sits on the boards of Given Technologies, Inc., PharmacoPhotonics, Inc. and BioNumerik Pharmaceuticals, Inc.

"I am proud to join the board at Pelikan Technologies, a truly revolutionary company that is taking impressive strides to improve the manner in which people with diabetes live with and manage their disease," said Mr. Ware. "I believe my experience in the medical technology and glucose monitoring industries can assist Pelikan in its mission of developing and commercializing innovative devices that dramatically improve the lives of people with diabetes."

"We believe that Denny's formidable background and range of outstanding achievements in our industry position him as an excellent addition to Pelikan's board of directors," stated Gerald Moeller, Ph.D., executive chairman of the board for Pelikan Technologies.

“We look forward to working with Denny and are excited for the important contributions that he will make to the company’s success.”

About Pelikan Technologies

Pelikan Technologies Inc. combines novel and proprietary blood sampling and measurement techniques with state-of-the-art miniaturization and automation technologies to develop superior hand-held medical diagnostic and monitoring devices. By addressing the pain and inconvenience associated with current methods of blood glucose testing, Pelikan’s product portfolio will eliminate the major obstacles to consistent glucose monitoring and vigorous diabetes management. The Pelikan Sun™ electronic lancing device strictly controls the entire lancing event, providing unparalleled comfort without calluses, bruising, or after-bleeding. In addition to Pelikan’s initial focus on diabetes and blood glucose monitoring, the company’s proprietary technology platform, supported by an extensive intellectual property portfolio, may be leveraged to develop state-of-the-art products for a variety of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems may eventually benefit from this novel technology.

For more information on Pelikan Technologies and the company’s innovative products, please visit www.pelikantechnologies.com.

###